Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial

Value in Health

Volumn 18, Issue 8, 2015, Pages 1079-1087

  Belozeroff, Vasily ^a   Chertow, Glenn M ^b   Graham, Christopher N ^c   Dehmel, Bastian ^a   Parfrey, Patrick S ^d   Briggs, Andrew H ^e  

^a AMGEN INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cinacalcet; cost effectiveness; dialysis; hyperparathyroidism

Indexed keywords

CINACALCET; PLACEBO; CALCIMIMETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE SYSTEM; HEMODIALYSIS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; UNITED STATES; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MARKOV CHAIN; MIDDLE AGED; MORTALITY; STATISTICAL MODEL;

ADULT; AGED; CALCIMIMETIC AGENTS; CINACALCET HYDROCHLORIDE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS; UNITED STATES;

EID: 84949751683     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.08.007     Document Type: Article

References (43)

1. W.G. Goodman, and L.D. Quarles Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics Kidney Int 74 2008 276 288
2. M. Jadoul, J.M. Albert, T. Akiba, and et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study Kidney Int 70 2006 1358 1366
3. J. Floege, J. Kim, E. Ireland, and et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population Nephrol Dial Transplant 26 2010 1948 1955
4. G.A. Block, P. Klassen, M.J. Lazarus, and et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2004 2208 2218
5. J.L. Natoli, R. Boer, B.H. Nathanson, and et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis BMC Nephrol 14 2013 1 16
6. Q.V. Doan, M. Gleeson, J. Kim, and et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease Curr Med Res Opin 23 2007 1561 1569
7. A. Lee, V. Belozeroff, X. Song, and et al. Costs of treatment and clinical events for secondary hyperparathyroidism Am J Pharm Ben 5 2013 e24 e35
8. S. Chiroli, C. Mattin, V. Belozeroff, and et al. Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study BMC Nephrol 13 2012 140
9. S.M. Moe, T.B. Drüeke, G.A. Block, and et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int 76 Suppl. 2009 S1 130
10. Amgen-USPI (2013). Cinacalcet PI US 2013.
11. R. Boer, A.M. Lalla, and V. Belozeroff Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States J Med Econ 15 2012 509 520
12. J.A. Ray, R. Borker, B. Barber, and et al. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA Value Health 11 2008 800 808
13. M. Eandi, L. Pradelli, S. Iannazzo, and et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy Pharmacoeconomics 28 2010 1041 1054
14. S. Iannazzo, M. Carsi, and S. Chiroli A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries Appl Health Econ Health Policy 10 2012 127 138
15. R. Garside, M. Pitt, R. Anderson, and et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective Nephrol Dial Transplant 22 2007 1428 1436
16. H. Komaba, K. Moriwaki, S. Goto, and et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan Am J Kidney Dis 60 2012 179 181
17. EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis N Engl J Med 367 2012 2482 2494
18. C. Baigent, M.J. Landray, C. Reith, and et al. on behalf of the SHARP investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial Lancet 377 2011 2181 2192
19. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, et al. for the TREAT investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
20. Y. Kubo, L.R. Sterling, P.S. Parfrey, and et al. Assessing the treatment effect estimate in a randomized controlled trial with extensive non-adherence: the EVOLVE trial Pharm Stat 14 2015 242 251
21. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
22. A.K. O'Sullivan, J. Rubin, J. Nyambose, and et al. Cost estimation of cardiovascular disease events in the US Pharmacoeconomics 29 2011 693 704
23. Bureau of Labor Statistics, US Department of Labor. Consumer Price Index - All Urban Consumers (Current Series). Bureau of Labor Statistics, US Department of Labor. 2013. Available from: www.bls.gov [Accessed July 25, 2013].
24. G.A. Block, D. Zaun, G. Smits, and et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients Kidney Int 78 2010 578 589
25. United States Renal Data System, Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
26. L. Tavazzi, A.P. Maggioni, R. Marchioli, and et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized double-blind placebo-controlled clinical trial Lancet 372 2008 1223 1230
27. C.M. O'Connor, D.J. Whellan, K.L. Lee, and et al. Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial Jama 301 2009 1439 1450
28. M.A. Pfeffer, K. Swedberg, C.B. Granger, and et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
29. A.H. Briggs, and B.J. O'Brien The death of cost-minimization analysis? Health Econ 10 2001 179 184
30. L. Bernard, D. Mendelssohn, E. Dunn, and et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom J Med Econ 16 2013 1 9
31. A. Lee, X. Song, I. Khan, and et al. Association of cinacalcet adherence and costs in patients on dialysis J Med Econ 14 2011 798 804
32. R. Narayan, R.M. Perkins, E.P. Berbano, and et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis Am J Kidney Dis 49 2007 801 813
33. P.S. Parfrey, G.M. Chertow, G.A. Block, and et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial J Clin Endocrinol Metab 98 2013 4834 4844
34. G.M. Chertow, Z.J. Lu, X. Xu, and et al. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols Hemodial Int 16 2011 188 197
35. L.B. Russell, M.R. Gold, J.E. Siegel, and et al. Role of cost-effectiveness analysis in health and medicine: consensus statement JAMA 276 1996 1172 1177
36. B. Canaud, L. Tong, F. Tentori, and et al. Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Clin J Am Soc Nephrol 6 2011 1651 1662
37. L.P. Garrison, E.C. Mansley, T.A. Abbott, and et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report - part II Value Health 13 2010 8 13
38. Grima DT, Mendelssohn DC, Mcfarlane P, et al. Inclusion of dialysis costs in cost-effectiveness analyses of therapies for patients in dialysis: a case study of sevelamer for the treatment of hyperphosphatemia. In: HTA For Health Systems Sustainability, 8th annual meeting. Rio De Janeiro, June 27-29, 2011.
39. P.J. Neumann, J.T. Cohen, and M.C. Weinstein Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold N Engl J Med 371 2014 796 797
40. Lee A, Song X, Belozeroff V, et al. Costs of care and major clinical events among chronic dialysis patients with and without treatment for sHPT: a descriptive study of claims data. Poster presented at: the American Society of Nephrology Annual Conference. Philadelphia, PA, November 8-13, 2011.
41. V. Belozeroff, K. Cooper, G. Hess, and C.L. Chang Healthcare use and costs before and after parathyroidectomy in patients on dialysis BMC Health Serv Res 13 2013 248
42. Red Book. 2013. Available from: www.micromedexsolutions.com. [Accessed July 25, 2013].
43. A.H. Briggs, P.S. Parfrey, N. Khan, and et al. Analysing Health-related Quality of Life in the EVOLVE trial: the joint impact of treatment and clinical events. Poster presented at: the American Society of Nephrology Annual Conference Atlanta, GA, November 2013 5 10